Rockefeller Capital Management L.P. Raises Stake in Bruker Corporation $BRKR

Rockefeller Capital Management L.P. raised its position in Bruker Corporation (NASDAQ:BRKR) by 741.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,522 shares of the medical research company’s stock after purchasing an additional 8,391 shares during the period. Rockefeller Capital Management L.P.’s holdings in Bruker were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orbis Allan Gray Ltd acquired a new position in shares of Bruker during the second quarter worth $192,735,000. Price T Rowe Associates Inc. MD raised its stake in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after buying an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock worth $86,663,000 after acquiring an additional 1,269,316 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 27.20% of the stock is currently owned by corporate insiders.

Bruker Stock Performance

NASDAQ BRKR opened at $61.64 on Monday. The firm’s fifty day moving average is $50.57 and its two-hundred day moving average is $45.01. Bruker Corporation has a one year low of $28.53 and a one year high of $64.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The firm has a market cap of $9.38 billion, a PE ratio of -256.83, a P/E/G ratio of 1.97 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the company posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several research analyst reports. TD Cowen raised their target price on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. UBS Group set a $60.00 target price on shares of Bruker in a report on Wednesday, June 24th. JPMorgan Chase & Co. increased their target price on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Finally, Wolfe Research initiated coverage on shares of Bruker in a research note on Monday, June 1st. They set a “peer perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Bruker currently has an average rating of “Hold” and an average price target of $54.54.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.